A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy
Status:
Completed
Trial end date:
2000-05-01
Target enrollment:
Participant gender:
Summary
A dose escalation scale consisting of 5 dosage levels is being used to determine the maximum
tolerated dose (MTD) of SU101. A minimum of 3 and a maximum of 6 patients will be enrolled at
each dose level. MTD is defined as the dose level immediately below that at which 2 or more
patients exhibit dose limiting toxicity.
Each treatment cycle is 21 days. Patients receive a 96 hour continuous IV infusion of SU101
on days 1-4.